308 related articles for article (PubMed ID: 32318876)
1. Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study.
Chen YC; Chen TH; Sun CC; Chen JY; Chang SS; Yeung L; Tsai YW
Acta Diabetol; 2020 Oct; 57(10):1181-1192. PubMed ID: 32318876
[TBL] [Abstract][Full Text] [Related]
2. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous Treatment Effects on Cardiovascular Diseases With Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas in Type 2 Diabetes Patients.
Yang CY; Lin WA; Su PF; Li LJ; Yang CT; Ou HT; Kuo S
Clin Pharmacol Ther; 2021 Mar; 109(3):772-781. PubMed ID: 32978779
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
[TBL] [Abstract][Full Text] [Related]
6. Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients With Type 2 Diabetes and the Incidence of Retinal Vein Occlusion in Taiwan.
Tsai HR; Lin YJ; Yeh JI; Lin SM; Liu PP; Chang YC; Lee YC; Loh CH; Huang HK
Invest Ophthalmol Vis Sci; 2024 Jun; 65(6):19. PubMed ID: 38864813
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitors attenuates osteoporosis in patients with diabetes: A nationwide, retrospective, matched-cohort study in Taiwan.
Chang CH; Lu CH; Chung CH; Su SC; Kuo FC; Liu JS; Li PF; Huang CL; Chen KC; Ho LJ; Kuo CC; Chang CY; Lin MS; Liu YC; Chu NF; Lee CH; Hung YJ; Hsieh PS; Lin FH; Hsieh CH; Chien WC
J Chin Med Assoc; 2022 Jul; 85(7):747-753. PubMed ID: 35648138
[TBL] [Abstract][Full Text] [Related]
8. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
Seong JM; Kim JJ; Kim HJ; Sohn HS
Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
[TBL] [Abstract][Full Text] [Related]
9. Effect of Dipeptidyl Peptidase-4 Inhibitors on the Risk of Bone Fractures in a Korean Population.
Ustulin M; Park SY; Choi H; Chon S; Woo JT; Rhee SY
J Korean Med Sci; 2019 Sep; 34(35):e224. PubMed ID: 31496139
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Kim S; Han SJ; Kim DJ; Lee KW; Kim HJ
J Diabetes Res; 2018; 2018():5246976. PubMed ID: 29850606
[TBL] [Abstract][Full Text] [Related]
11. Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
Hung CT; Liu JS; Cheng CY; Chung CH; Chiang CP; Chien WC; Wang WM
J Dermatol; 2020 Mar; 47(3):245-250. PubMed ID: 31885117
[TBL] [Abstract][Full Text] [Related]
12. Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.
Driessen JH; van den Bergh JP; van Onzenoort HA; Henry RM; Leufkens HG; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):421-428. PubMed ID: 27943565
[TBL] [Abstract][Full Text] [Related]
13. Association of dipeptidyl peptidase-4 inhibitor use and the risk of asthma development among type 2 diabetes patients.
Li PF; Chung CH; Liu JS; Lu CH; Su SC; Kuo FC; Ho LJ; Chen KC; Su YT; Chu NF; Lee CH; Hsieh CH; Hung YJ; Lin FH; Chien WC; Liang YJ
Ther Adv Respir Dis; 2022; 16():17534666221135320. PubMed ID: 36448591
[TBL] [Abstract][Full Text] [Related]
14. Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors.
Lee M; Sun J; Han M; Cho Y; Lee JY; Nam CM; Kang ES
Diabetes Care; 2019 Nov; 42(11):2057-2064. PubMed ID: 31431452
[TBL] [Abstract][Full Text] [Related]
15. Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes: A retrospective cohort study.
Chin HJ; Nam JH; Lee EK; Shin JY
Medicine (Baltimore); 2017 Jun; 96(25):e7213. PubMed ID: 28640111
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study.
Hou WH; Chang KC; Li CY; Ou HT
Br J Clin Pharmacol; 2018 Sep; 84(9):2029-2039. PubMed ID: 29766544
[TBL] [Abstract][Full Text] [Related]
17. Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.
Chou HC; Chen WW; Hsiao FY
Drug Saf; 2014 Jul; 37(7):521-8. PubMed ID: 24859164
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Seong JM; Yee J; Gwak HS
Br J Clin Pharmacol; 2019 Aug; 85(8):1719-1727. PubMed ID: 30964554
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes in Taiwan: A Population-Based Cohort Study.
Lai YJ; Hu HY; Chen HH; Chou P
Medicine (Baltimore); 2015 Oct; 94(43):e1906. PubMed ID: 26512613
[TBL] [Abstract][Full Text] [Related]
20. Use of dipeptidyl peptidase-4 inhibitors and the risk of arthralgia: Population-based cohort and nested case-control studies.
Wang CY; Fu SH; Yang RS; Hsiao FY
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):500-506. PubMed ID: 30724413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
